NAUT
NAUTILUS BIOTECHNOLOGY, INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $2.27 | $2.36 | +4% |
| Millennium Management | Q1 2025(8Q snapshot) | 5Q | $1.71 | $2.36 | +38% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $2.69 | $2.36 | -12% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors | Q3 2024 | Q1 2026 | → $2.69 | +20% |
| AQR Capital Management | Q2 2025 | Q4 2025 | → $1.80 | +108% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Nautilus Biotechnology, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001231919-26-000599Jun 4, 2026
- Form 40001378830-26-000003Mar 4, 2026
- Form 40001856938-26-000001Mar 4, 2026
- Form 40001857948-26-000001Mar 4, 2026
- Form 40001378830-26-000001Mar 4, 2026
- Form 40001856744-26-000001Mar 4, 2026
- Form 40001378831-26-000001Mar 4, 2026
- Form 40001865778-26-000001Mar 4, 2026
- Form 40002037191-26-000001Mar 4, 2026
- Form 40002037191-25-000004Nov 10, 2025
- Form 40001378830-25-000003Sep 9, 2025
- Form 40001865778-25-000003Sep 5, 2025
- Form 40001808805-25-000064Jun 25, 2025
- Form 40001808805-25-000063Jun 25, 2025
- Form 40001808805-25-000062Jun 25, 2025
Fundamentals
XBRL · NAUTILUS BIOTECHNOLOGY, INC.Annual figures sourced directly from NAUTILUS BIOTECHNOLOGY, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Nautilus Biotechnology, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- DEF 14AProxy statementApr 28, 2026
- 10-QQuarterly reportApr 28, 2026
- 8-KMaterial eventApr 28, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventNov 4, 2025
- 10-QQuarterly reportOct 28, 2025
- 8-KMaterial eventOct 28, 2025
- 10-QQuarterly reportJul 31, 2025
- 8-KMaterial eventJul 31, 2025
- 8-KMaterial eventJun 23, 2025
- 8-KMaterial eventMay 2, 2025
- DEF 14AProxy statementApr 29, 2025
- 10-QQuarterly reportApr 29, 2025
- 8-KMaterial eventApr 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $2.69 | $2.36 | -12% |
| AQR Capital Management | Q2 2025 | Q4 2025 | $0.87 | $1.80 | +108% |
| Millennium Management | Q1 2025 | open | $1.71 | $2.36 | +38% |
| Citadel Advisors | Q3 2024 | Q1 2026 | $2.24 | $2.69 | +20% |
| Renaissance Technologies | Q3 2024 | open | $2.27 | $2.36 | +4% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.